21, 2025 (HealthDay News) -- Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet promising study from Memorial Sloan Kettering Cancer Center. The study followed 16 patients, including Barbara Brigham, who joined the trial a...
In trials, a vaccine for pancreatic cancer developed by Sloan-Ketterin and BioNTech showed promise, but researchers say it is still too early to tell.Featured 2025 PGA Championship Leaderboard 2025 Preakness predictions, odds 2025 NBA Playoff Schedule Follow Us On YouTube Facebook Instagram...
Could weight loss drugs help prevent cancer? Here's what a new study found. Alcohol-related cancer deaths doubled from 1990 to 2021, study finds FDA expands COVID vaccine warning about possible side effect U.S. reports cases of new COVID variant NB.1.8.1 behind surge in China ...
In the new study, Vinod Balachandran, an assistant attending surgeon at Memorial Sloan Kettering Cancer Center in New York City, and his colleagues targeted pancreatic cancer patients’ own tumor neoantigens using mRNA technology—the same technology used to create the remarkably successful COVID vacc...
Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line Zsófia Szász Angéla Takács László Kőhidai ResearchOpen Access07 May 2025 Scientific Reports Volume: 15, P: 15925 All Research & Reviews News...
Therapeutic failures may thus be avoided.doi:10.1007/0-387-21600-6_33Eileen M. O'ReillySpringer New YorkO'Reilly EM: Vaccine therapy for pancreatic cancer. In: Pancreatic Cancer, Evans DB, Pisters PWT, Abbruzzese JL (Ed), pp 347-356, Springer-Verlag, New York, 2002....
We previously conducted a phase I clinical trial combining the HLA-A*2402-restricted KIF20A-derived peptide vaccine with gemcitabine for advanced pancreatic cancer (PC) and confirmed its safety and immunogenicity in cancer patients. In this study, we conducted a multicenter, single-armed, phase II...
In asmall study of 16 cancer patients, scientists have managed to design a vaccine that provoked an immune response in half of those who signed up — and that half displayed no signs of relapse during the study. All eight of those responders made T-cells to combat their tumors, which have...
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients1, yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3. Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine
Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional CD8+ T cells in patients with pancreatic ductal adenocarcinoma (PDAC), potentially delaying disease recurrence.